UTHR
United Therapeutics Corp

2,411
Loading...
Loading...
News
all
press releases
Is IPF the Next Big Market Opportunity for United Therapeutics?
UTHR reports strong TETON-2 results for Tyvaso in IPF, showing lung function gains and eyeing a major new market.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Top Stock Reports for NextEra Energy, U.S. Bancorp and Air Products & Chemicals
NextEra Energy expands its renewable pipeline, U.S. Bancorp builds on earnings momentum, and Air Products eyes growth despite headwinds.
Zacks·2d ago
News Placeholder
Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE?
Merck eyes new launches like Capvaxive and Winrevair, among others, to drive long-term growth as Keytruda nears loss of exclusivity.
Zacks·13d ago
News Placeholder
Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·21d ago
News Placeholder
UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals
United Therapeutics hit a record high after its Tyvaso study in idiopathic pulmonary fibrosis met key goals and showed broad patient benefits.
Zacks·29d ago
News Placeholder
MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results
United Therapeutics plans to meet with the U.S. FDA before the end of the year to discuss adding idiopathic pulmonary fibrosis to Tyvaso’s label.
Stocktwits·1mo ago
News Placeholder
This Pharma Stock Soared 36% Today And Drew Price Target Hikes From Wall Street – More Details Inside
The company reported that Tyvaso demonstrated superiority over the placebo in terms of the change in absolute forced vital capacity, increasing by 95.6 mL from baseline to week 52 in patients with idiopathic pulmonary fibrosis in the trial.
Stocktwits·1mo ago
News Placeholder
Why Is United Therapeutics (UTHR) Up 11.9% Since Last Earnings Report?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·1mo ago
News Placeholder
MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together
The 2018 agreement between the companies led to US FDA approval of Tyvaso DPI in May 2022 and included an option for United Therapeutics to expand the license to include additional active ingredients.
Stocktwits·1mo ago
News Placeholder
Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?
MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.
Zacks·2mo ago

Latest UTHR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.